Objectives Expression of anti-Saccharomyces cerevisiae antibodies (ASCA) identifies patients and individuals at risk for Crohn's disease and has also been reported in 40-60% of celiac disease (CD) cases, suggesting a role of host response to enteric microbiota in the development of inflammatory lesions. In this prospective study in patients with suspicion of CD, we evaluate the frequency and association of ASCA to serological responses for other host microbial targets formally associated with Crohn's disease, including the Pseudomonas fluorescens associated sequence I2 and a Bacteroides caccae TonB-linked outer membrane protein, OmpW. Methods Small bowel mucosal biopsies were taken from 242 patients with suspicion of CD, their sera were tested for antibodies to tissue transglutaminase (tTG), ASCA, I2, and OmpW. Eighty adult healthy blood donors were used as controls.
Introduction
Celiac disease (CD) is a gluten-induced disease with small bowel mucosal damage manifesting with villous shortening, crypt hyperplasia, and inflammation usually recovering on a gluten-free diet (GFD) [1] [2] [3] . Both CD and inflammatory bowel diseases (IBD) are characterized by the presence of distinct autoantibodies. Immunoglobulin A (IgA) autoantibodies to tissue transglutaminase (tTG) are commonly used for screening and diagnosing of CD [4] [5] [6] . In some cases, however, tTG antibodies are known to be found as "false positive" results in patients with IBDmainly in Crohn's disease [7] . Anti-Saccharomyces cerevisiae antibodies (ASCA) have been suggested to be a specific marker of Crohn's disease, as several studies have provided evidence of seroreactivity against the S. cerevisiae both in adult (56%) and pediatric (67%) Crohn's disease patients [8] [9] [10] [11] [12] [13] [14] . Recently, ASCA positivity has also been detected in up to 40-60% of CD cases [15] [16] . Consistent evidence of linkage to IBD3 (6p21. , an area which encompasses the human leukocyte antigen (HLA) complex, has been demonstrated in IBD, both in Crohn's disease and in ulcerative colitis [17] . A strong HLA association with CD is also evident. Furthermore, chromosomal region 5q31 has been demonstrated in genome-wide studies to be linked to both CD and Crohn's disease [18] [19] [20] .
Commensal luminal bacteria induce dysregulated mucosal immune responses which may contribute to the pathogenesis of Crohn's disease [21] . Indeed, a number of microorganisms and their products have been implicated in Crohn's disease, as has been shown in studies proving their presence in mucosal lesions and the occurrence of serologic antimicrobial host responses (e.g., enteroadhesive Escherichia coli, MAP, Pseudomonas fluorescens, Bacteroides caccae, ASCA) [8] [9] [10] [11] [12] [13] [22] [23] [24] [25] [26] [27] . For example, high prevalence of antibodies to P. fluorescens associated sequence I2 has been found in adult and pediatric patients with Crohn's disease (54% and 60%, respectively) [13, 22] . In experimental mouse models, mechanistic evidence for the role of P. fluorescens in the pathogenesis of Crohn's disease has been reported [13, 23] .
The presence of anaerobic bacteria has been thought to be critical in the development of inflammatory lesions [28] . Serum antibodies to B. caccae TonB-linked outer membrane protein, OmpW, immunoglobulin (Ig) class A levels have been reported to be elevated in patients with Crohn's disease [13, 24] . Among these microbial candidates, the combination of antimicrobial specificities is a unique and stable phenotype with a substantial genetic contribution [29] . These observations support the concept of a mosaic of host traits controlling microbial colonization and regulating inflammation. Accordingly, heterogeneity in such traits is predicted to confer selective susceptibility to distinct microorganisms for disease pathogenesis in different patients.
The occurrence of ASCA also in CD patients raises the possibility that a biology similar to that in IBD may contribute to disease risk in this small bowel disorder. To test this, it is necessary to address the serological responses to a broader panel of microbial targets that have proved informative in Crohn's disease, especially at the earliest stages of disease onset. This study attempts a prospective assessment of the frequency of ASCA seropositivity in children and adults with suspicion of CD. In addition, it provides data of host serologic responses to additional bacterial targets typical for IBD (the P. fluorescensassociated sequence I2 and to a B. caccae TonB-linked outer membrane protein, OmpW) in this CD population. Surgery, Tampere University Hospital were evaluated in a prospective manner. Eighty adult healthy blood donors served as a healthy control group. Upper gastrointestinal endoscopies with multiple biopsies from duodenum were performed on all 242 patients. CD diagnosis was based on severe partial or subtotal villous atrophy with crypt hyperplasia and on the response to a GFD [1] . At the same time, sera were drawn for antibody testing.
Materials and Methods

Patients
Serum Antibody Tests
Sera from patients were tested for antibodies to tTG (Celikey tTG IgA, Phadia, Freiburg, Germany) and/or endomysium antibodies (Ema) [30] and titers 1:_5 were considered positive. An enzyme immunoassay (EIA) kit (QUANTA LiteTM ASCA, INOVA Diagnostics Inc., San Diego, CA, USA) was used for the determination of anti-S. cerevisiae antibodies (ASCA) of both IgG and IgA isotypes from the sera. The kit included positive and negative controls and was used according to the manufacturer's instructions. Quantitative results in arbitrary EIA units were obtained from standard curves defined by the manufacturer, but the results were statistically handled as qualitative. Equivocal/borderline results were interpreted as negative. Results exceeding 25 U for IgG and/or IgA ASCA were regarded as positive.
Sera for the determination of anti-I2 and anti-OmpW IgA levels were stored at −70°C until testing. In our laboratory, E. coli XL-1-blue and E. coli BL-21 (Stratagene, La Jolla, California, USA) strains were used for all cloning and recombinant expression experiments. I2-GST and OmpW were produced by using the antigen purification techniques reported previously [23, 24] . Sera were analyzed with IgA enzymelinked immunosorbent assays (ELISA) to I2 and OmpW [13] . The cut-off level for positivity in the IgA-class ELISA test was set at 0.5 (for I2-GST) and 0.6 and 1.0 (for OmpW in children and adults, respectively) [13, 22] (see also Results).
Biopsy Specimen Processing and Immunohistochemical Staining
Two to three biopsy specimens were processed by routine histological methods and sections of formalin-fixed and paraffin-embedded specimens were stained with hematoxylin and eosin. Small bowel mucosal morphology (ratio of villous height and crypt depth) was determined in 162 adult patients with suspicion of CD as previously described [31] .
Statistical Analysis
Optical densities of antibody ELISA tests were expressed by means with 95% confidence interval of the mean. Other continuous variables were expressed by medians with range due to the skewed distribution. The differences between categorical variables were tested using the Pearson Chisquare test or Fisher's exact test. Statistical calculations were carried out with SPSS for Windows (version 14.0.2; SPSS INC., Chicago, IL, USA). The analyses for specificity and sensitivity values were performed.
Ethical Considerations
The study protocol was approved by the Ethical Committee of Tampere University Hospital and informed consent was obtained from the parents and also from the children when appropriate.
Results
Biopsy-proven CD was confirmed in 134 patients (86 adults and 48 children). One hundred and eight patients (87 adults and 21 children) were excluded for CD on biopsy. These cases served as disease controls. The diagnosis of children with non-CD disease were abdominal pain NUD (n=10), anorexia nervosa (n=1), food allergy with gastrointestinal symptoms (n=1), and positive CD antibodies (tTG antibodies) (n=9). Adult non-CD cases were diagnosed to have gastroesophageal reflux disease and dyspepsia. From all CD cases positive tTG antibody titers were detected in 127/134 (95%), in 10/108 (9%) of non-CD patients and none (0%) of healthy controls. Demographic data and ages of the study population are shown in Table I .
Sixty-two out of 134 (46%) of those having CD were ASCA (IgA and/or IgG class) positive at the time of diagnosis. Frequency of ASCA positivity was significantly elevated in adult CD patients when compared to the disease controls (16/108, 15%) or to healthy individuals (0/80, 0%) (Table II) . Serum titers of ASCA IgA and IgG were significantly elevated in CD patients when compared to non-CD patients ( p<0.001, p <0.001), both in adults ( p<0.001, p<0.001) and in children (p=0.005, p=0.025).
Ninety-two out of 131 (70%) biopsy-proven CD patients, 65/107 (61%) of non-CD patients and 25/80 (31%) of healthy controls showed positive titers of I2 (specificity 59%, sensitivity 79%). Specificity and sensitivity of the I2 antibodies for adult CD cases were 82% and 75% and for pediatric CD cases 67% and 42%, respectively. Frequencies of I2 positivity in different study groups are presented in Table II . Anti-I2 levels in the sera were significantly higher in adult CD patients than in those excluded for the disease or in healthy controls ( p<0.001, p<0.001; median of absorbances) (Fig. 1a) .
Positive seroreactivity to OmpW antibodies seemed to increase with age (Fig. 2) . The cut-off levels for OmpW antibodies were set on the basis of age and the ability of the tests to distinguish patients with CD from the healthy controls and according to the information in the previous data [13] . Eighty out of 131 CD patients (61%), 65/106 (61%) of non-CD patients and 19/80(24%) of healthy controls were positive for OmpW when the cut-off level for seropositivity was set at values 0.6 (pediatric cases) (specificity 81%, sensitivity 62%,) and 1.0 (adult cases) (specificity 62%, sensitivity 50%). When focusing on the whole CD study group, sensitivity to OmpW antibodies was 81%, specificity 54%. Frequency of positive serological response to OmpW was similar in patients with CD and disease controls excluded for CD (Table II) . Serum antiOmpW levels were significantly higher in CD patients than in the healthy control group (p<0.001; Fig. 1b ). Ninety percent of CD patients were seropositive for at least one of the microbial antigens tested here. Moreover, many CD patients had immune reactivity to more than one of the microbial antigens examined in the present study (Fig. 3) .
Data on small bowel mucosal morphology (ratio of villous height and crypt depth) were available for 79 adult CD patients. A significant association was observed for villous atrophy and frequency of ASCA positivity ( p= 0,027). ASCA levels were high within patients with low ratio of villous height and crypt depth when compared to patients with normal mucosal morphology. By contrast, the association between this mucosal morphology and I2 or OmpW positivity was not significant ( p=0.847 and p= 0.711, respectively).
Discussion
This study demonstrated a mosaic of disease-related serological responses to microbial antigens in children and adults with CD, some of which are also associated with the duration of the disease. Here, these findings in relation to CD predisposition and pathogenesis are discussed. The understanding of such serologic microbial signatures in IBD is also assessed.
As expected, in this study, 95% of biopsy-proven CD patients were positive for tTG antibodies, a distinct characteristic for CD [5, 32] . There were also nine patients who showed positive seroreactivity to tTG but who in any case did not meet the criteria for CD (ESPGHAN, 1) and hence were considered as disease controls. They may be an interesting population for further assessment due to the possibility that they represent individuals with latent CD [6] . Sjöberg et al. have reported increased tTG IgG antibody titers also in patients with ulcerative colitis and Crohn's disease [7] . It may be that those so-called false positive cases among patients with IBD have or will develop CD later on in life.
ASCA has been described as a specific marker of Crohn's disease in adults and children [8-13, 26, 33] . ASCA positivity has been reported in a proportion of adult CD patients [15, [34] [35] [36] [37] . Here, we demonstrate an increased ASCA in both adult (58%) and pediatric (17%) patients with CD. The higher prevalence of ASCA seroreactivity found here in adult CD patients is notable compared to that found in children and to earlier studies on adults. This may reflect a longer duration of disease in our adult CD patients. Serum titers of ASCA IgA and IgG were significantly increased in CD patients. These titers were similar as reported in Crohn's disease patients in previous studies [14] . In IBD, ASCA positivity is associated with increased intestinal permeability [38] . In CD gliadin induces zonulin release and zonulin-dependent pathway of increased intestinal permeability [39] [40] . Thus, increased ASCA in CD adults may be due to their longer exposure to gluten, recurrent damage to the small bowel mucosa, and more numerous episodes of microbial challenge, all resulting in increased permeability.
Alternatively, the high ASCA seropositivity in this adult CD cohort may reflect additional traits related to the Finnish heritage. In IBD, too, ASCA positivity may be a CD celiac disease, ASCA anti-Saccharomyces cerevisiae antibodies, I2 anti-I2, antibodies to P. fluorescens associated sequence I2, OmpW a Bacteroides caccae TonB-linked outer membrane protein.
For p values, patient groups were compared to the disease controls (non-CD disease) (p1) and healthy adult control group (p2). *I2 analyses were available from 131 CD cases (86 adults and 45 children) and from 107 non-CD cases (86 adults and 21 children). *OmpW analyses were available from 131 CD cases (86 adults and 45 children) and from 106 non-CD cases (87 adults and 19 children).
Healthy adult controls, n=80
Adult Non-CD, n=86 Adult CD, n=86 Child Non-CD, n=21 Child CD, n=45 marker of genetic subsets of disease with distinct clinical traits and serve as a preclinical trait in those subsets [38, [41] [42] [43] . Elevated intestinal permeability has been observed in CD patients and their relatives [44] [45] [46] [47] . As suggested by Granito et al., ASCA positivity may also be associated with silent CD as it occurs in a proportion of CD patients before they develop any clinical symptoms [48] . It may be fruitful to evaluate whether ASCA can distinguish cohorts at distinct disease risk or course in CD.
We also report for the first time a high prevalence of antibodies to the P. fluorescens-associated sequence I2 and to a B. caccae TonB-linked outer membrane protein, OmpW in CD. I2 and OmpW were commonly found to be elevated in biopsy-proven CD patients (70% and 61%, respectively). A high prevalence of anti-I2 and anti-OmpW antibodies has previously been reported in children and adults with Crohn's disease [13, 19, 49] . It is interesting to note that 90% of CD patients showed positive seroreactivity to at least one of the microbial antigens (ASCA, I2, OmpW) tested in the present study. These findings indicate that there is a shared mosaic of antimicrobial seroresponse in CD and IBD. As in IBD, this suggests that immune responses to commensal enteric bacteria may play a role in inducing mucosal damage in CD. If this is the case, microbial seroreactivity may reflect immune reaction and inflammation of the small intestine in CD patients, or in patients with other upper gastrointestinal symptoms. Altered permeability in the small intestine may explain the frequent detection of seroreactivity to different various microbial antigens in patients with suspicion of CD [38] [39] [44] [45] [46] [47] . In addition, increasing age was associated with positive seroreactivity for anaerobic bacterial antigen in this study. This may be caused by exposure to different environmental factors (food, medications) or to genetic background and age.
Recently, it has been shown that seroreactivity to microbial components in Crohn's disease is associated with disease severity, progression, and the frequency of complications [12, 50, 51] . In contrast to the previous study, we showed here that the frequency of ASCA positivity in CD patients was significantly associated with the grade of small bowel mucosal morphology [17] . ASCA positivity has reported to disappear or decrease after GFD [35] . We will get more information concerning ASCA and other microbial seromarkers during GFD in our ongoing follow-up studies. A larger study would be required for adequate power to better detect a relationship between CD-associated cellular responses and the microbial seroresponses.
In conclusion, this study reveals a mosaic of serological bacterial responses in CD, notably a new identification of the P. fluorescens-associated sequence I2 and to a B. caccae TonB-linked outer membrane protein, OmpW. The present findings provide important evidence for a contribution of such responses to the pathogenic mechanisms of inflammation in CD and possibly in those of other upper intestinal diseases. These serologic specificities may provide new tools for the detection and differentiation of patients with such gastrointestinal diseases. 
